Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Breast Cancer
Interventions: Letrozole, Placebo; Drug
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 30 Years to 69 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 15 Years to 30 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cardiovascular Disease, High Blood Pressure
Interventions: Million Hearts ABCS 6 Months, Million Hearts ABCS 9 Months, Million Hearts ABCS 12 Months, Million Hearts ABCS 15 Months, Standard Care Regimen 9 Months, Standard Care Regimen 12 Months, Standard Care Regimen 15 Months, Standard Care Regimen 18 Months, Standard Care Regimen 21 Months, Standard Care Regimen 24 Months, Standard Care Regimen 27 Months, Follow Up Post Intervention 21 Months, Follow Up Post Intervention 24 Months, Follow Up Post Intervention 27 Months, Follow Up Post Intervention 30 Months, Follow Up Post Intervention 33 Months; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions: ALN-PCSSC, Normal Saline; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: Regorafenib; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Including Dallas, TX, Ocala, FL, Denver, CO, Florida

Conditions: Prostate Cancer
Interventions: 2141-V11 Antibody; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Hypertension
Interventions: Self-Titration; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Thrombosis
Interventions: Vitamin K, 20mg; Dietary Supplement
Lead sponsor: Stephan Moll, MD; Other
Eligibility: 20 Years to 85 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: Home Based Asthma Education; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Years to 6 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pregnancy Complications, Mental Health Issue, Depression, Anxiety, Pregnancy, High Risk, Biological Clock Disturbance
Interventions: Step count goal, Actigraph watch; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 45
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more

Conditions: Colorectal Cancer, Pancreatic Cancer, Lung Cancer
Interventions: Vitamin C; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Prostate Cancer
Interventions: high-LET heavy ion therapy, low-LET photon therapy; Radiation
Lead sponsor: Proton Radiation Oncology Group; Other
Eligibility: Male only
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 2
States / cities: Loma Linda, California • Boston, Massachusetts

Conditions: Hypolipoproteinemia, Hypercholesterolemia, Dyslipidemia, Hyperlipidemia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1976
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Dental Caries
Interventions: Fluoride varnish; Drug
Lead sponsor: University of Washington; Other
Eligibility: 36 Months to 71 Months
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Lower Valley, Yakima County, Washington

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions: Angel® Catheter; Device
Lead sponsor: BiO2 Medical; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 95 Years · Male only
Enrollment: 60 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Soft Contact Lenses, Myopia
Interventions: Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye, Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 38 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Ficlatuzumab, Cytarabine; Drug
Lead sponsor: C. Babis Andreadis; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: La Jolla, California • Orange, California • Tampa, Florida + 9 more

Conditions: Leukemia
Interventions: bryostatin 1, cytarabine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 4
States / cities: New York, New York • Houston, Texas • Richmond, Virginia

Conditions: High-Grade Gliomas
Interventions: Bevacizumab, Irinotecan hydrochloride; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Oropharynx Squamous Cell Carcinoma
Interventions: Nivolumab, Carboplatin, Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Study of Breast Cancer Prevention by Letrozole in High Risk Women

Feasibility of an Early Detection Program for Early Psychosis on a College Campus

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Antihypertensive Self-titration in US Primary Care

Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation

Reducing Asthma Morbidity In High Risk Minority Preschool Children

Psychobiological Interventions in Pregnancy

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer

Yakima Head Start Fluoride Varnish Study

Angel® Catheter Early Feasibility Clinical Study

PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

DAILIES TOTAL1 Versus ACUVUE TruEye - Effects on the Biology of the Ocular Surface and Lid Margin

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

Bevacizumab and Irinotecan to Treat Brain Tumors

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer